Shopping Cart
- Remove All
- Your shopping cart is currently empty
Cevoglitazar (LBM-642) is a PPARɑ agonist and PPARγ agonist. Cevoglitazar potently reduces food intake and body weight in obese mice and cynomolgus monkeys.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $108 | In Stock | |
5 mg | $260 | In Stock | |
10 mg | $390 | In Stock | |
25 mg | $653 | In Stock | |
50 mg | $928 | In Stock | |
100 mg | $1,260 | In Stock | |
500 mg | $2,530 | In Stock |
Description | Cevoglitazar (LBM-642) is a PPARɑ agonist and PPARγ agonist. Cevoglitazar potently reduces food intake and body weight in obese mice and cynomolgus monkeys. |
In vivo | Cevoglitazar (0.5 mg/kg; 7 d) plasma levels of glucose and insulin were normalized.[1] Cevoglitazar (50 and 500 mg/kg; obese and insulin-resistant cynomolgus monkeys; 4 weeks) lowered food intake and body weight in a dose-dependent manner. In these animals, cevoglitazar also reduced fasting plasma insulin and, at the highest dose, reduced hemoglobin A1c levels by 0.4%.[1] Cevoglitazar (5 mg/kg) reduced BW gain and adiposity, independent of food intake. In the muscle, cevoglitazar improves the lipid profile via both PPARalpha- and PPARgamma-mediated mechanisms, and cevoglitazar reduced hepatic lipid concentration below baseline levels (p < 0.05). Metabolic profiling showed that in the liver, cevoglitazar functions largely through PPARalpha agonism resulting in increased beta-oxidation. Cevoglitazar only induced small changes to the lipid composition of visceral fat.[2] |
Alias | LBM-642, LBM642, LBM 642 |
Molecular Weight | 558.53 |
Formula | C27H21F3N2O6S |
Cas No. | 839673-52-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 50 mg/mL (89.52 mM) | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.